

[Warfarin](#)

Essential medicine status

Section:

[10. Medicines affecting the blood](#) [10.2. Medicines affecting coagulation](#)

ATC codes: [B01AA03](#)

EMLc

Indication

Cerebral ischaemic stroke due to embolic occlusion ICD11 code: [8B11.2](#)

INN

Warfarin

Medicine type

Chemical agent

List type

Core (EML)

Complementary (EMLc)

Formulations

Oral > Solid > tablet: 5 mg (scored) (sodium) ; 1 mg (scored) (sodium) ; 2 mg (scored) (sodium) ; 0.5 mg (scored) (sodium) (EMLc) ; 3 mg (scored) (sodium)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1982 ([TRS 685](#))

Changed in 1987 ([TRS 770](#))

Changed in 2007 ([TRS 950](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

[acenocoumarol](#) (ATC codes: [B01AA07](#))

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Warfarin](#)

DrugBank

[Warfarin](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of warfarin 3 mg scored tablets to the EML and EMLc; - to modify the formulation descriptions to better describe the available dosage forms; - to specify acenocoumarol as a therapeutic alternative to warfarin.